Dr. Khaled on Recognition and Treatment of TA-TMA

Video

Samer K. Khaled, MD, discusses current recognition and treatment strategies for transplant-associated thrombotic microangiopathy.

Samer K. Khaled, MD, medical director of hematology and HCT Clinical Operations at City of Hope, discusses current recognition and treatment strategies for transplant-associated thrombotic microangiopathy (TA-TMA).

The complication of TA-TMA occurs posttransplant, and patients with this condition often have a poor prognosis with an increase in mortality and morbidity. Therefore, Khaled suggests recognizing this condition early to begin treatment as soon as possible. Some data show that early treatment with a complement blockade can improve the outcomes for these patients, according to Khaled.

Research for treating TA-TMA is still in its early stages and the treatment procedure depends on the physician recognition of the condition, says Khaled. In the pediatric space, there are more efforts into systematically looking or screening for the markers of TA-TMA to recognize the complication early, concludes Khaled.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD